白云山:地塞米松磷酸钠注射液通过仿制药一致性评价

南方财经网
Jul 09

  南财智讯7月9日电,白云山公告,公司控股子公司广州白云山天心制药股份有限公司收到国家药监局核准签发的《药品补充申请批准通知书》,地塞米松磷酸钠注射液(1ml:5mg)通过仿制药质量和疗效一致性评价。

(文章来源:南方财经网)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10